Literature DB >> 8945586

Intranasal immunization induces long-term protection in mice against a Chlamydia trachomatis genital challenge.

S Pal1, E M Peterson, L M de la Maza.   

Abstract

In an attempt to confer long-term protective immunity, BALB/c female mice were immunized intranasally with 10(4) inclusion-forming units (IFU) of the Chlamydia trachomatis mouse pneumonitis biovar (MoPn). Animals were subsequently challenged in the ovarian bursa with 10(5) C. trachomatis MoPn IFU at 60, 120, or 180 days post-intranasal immunization. Two control groups were included in the study. One control was sham immunized and mock challenged, and another group was sham immunized and challenged with 10(5) C. trachomatis MoPn IFU. Vaginal cultures were collected at regular intervals following the intrabursal challenge. In comparison with the sham-immunized mice, the animals that were intranasally immunized with C. trachomatis had significant protection, as shown by a reduction in the number of animals that had positive vaginal cultures and by a decrease in the intensity and length of the shedding. Furthermore, histopathological characterization of the genital tract following challenge, in the three groups of mice, showed a minimal inflammatory infiltrate in the C. trachomatis-immunized animals, when compared with the sham-immunized control group. Subsequently, the three groups of female mice that were challenged at 60, 120 and 180 days postimmunization were mated at 6 weeks following the challenge. Overall, in the mice intranasally immunized with C. trachomatis the fertility rates and the number of embryos were similar to those in the sham-immunized and mock-challenged group. In contrast, there was a significant increase in infertility in the groups of mice that were sham immunized and C. trachomatis challenged. In conclusion, intranasal immunization with C. trachomatis induces long-term protection against a genital challenge as shown by a decrease in the infection and infertility rates when compared with sham-immunized animals. Thus, this model may help to characterize the parameters of the immune response that are important in maintaining long-term protection and may aid in identifying the antigenic determinants involved in eliciting protection.

Entities:  

Mesh:

Year:  1996        PMID: 8945586      PMCID: PMC174528          DOI: 10.1128/iai.64.12.5341-5348.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  48 in total

1.  Immunity to chlamydial infections of the eye. I. The role of circulatory and secretory antibodies in resistance to reinfection with guinea pig inclusion conjunctivitis.

Authors:  E S Murray; L T Charbonnet; A B MacDonald
Journal:  J Immunol       Date:  1973-06       Impact factor: 5.422

2.  A solid-phase immunoenzymatic technique for the enumeration of specific antibody-secreting cells.

Authors:  J D Sedgwick; P G Holt
Journal:  J Immunol Methods       Date:  1983-02-25       Impact factor: 2.303

Review 3.  Chlamydial salpingitis.

Authors:  L Weström; P A Mårdh
Journal:  Br Med Bull       Date:  1983-04       Impact factor: 4.291

4.  Infertility as a consequence of chlamydial infection of the upper genital tract in female mice.

Authors:  C E Swenson; J Schachter
Journal:  Sex Transm Dis       Date:  1984 Apr-Jun       Impact factor: 2.830

5.  Chlamydial serology in infertile women by immunofluorescence.

Authors:  R Punnonen; P Terho; V Nikkanen; O Meurman
Journal:  Fertil Steril       Date:  1979-06       Impact factor: 7.329

6.  Use of enteric vaccines in protection against chlamydial infections of the genital tract and the eye of guinea pigs.

Authors:  R L Nichols; E S Murray; P E Nisson
Journal:  J Infect Dis       Date:  1978-12       Impact factor: 5.226

7.  Correlation of host immune response with quantitative recovery of Chlamydia trachomatis from the human endocervix.

Authors:  R C Brunham; C C Kuo; L Cles; K K Holmes
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.441

8.  Comparison of a single-antigen microimmunofluorescence assay and inclusion fluorescent-antibody assay for detecting chlamydial antibodies and correlation of the results with neutralizing ability.

Authors:  E M Peterson; R Oda; P Tse; C Gastaldi; S C Stone; L M de la Maza
Journal:  J Clin Microbiol       Date:  1989-02       Impact factor: 5.948

9.  Correlation between serum antichlamydial antibodies and tubal factor as a cause of infertility.

Authors:  R B Jones; B R Ardery; S L Hui; R E Cleary
Journal:  Fertil Steril       Date:  1982-11       Impact factor: 7.329

10.  Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis.

Authors:  H D Caldwell; J Kromhout; J Schachter
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

View more
  34 in total

1.  Chlamydial colonization of multiple mucosae following infection by any mucosal route.

Authors:  L L Perry; S Hughes
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

2.  Generation of female genital tract antibody responses by local or central (common) mucosal immunization.

Authors:  H Y Wu; S Abdu; D Stinson; M W Russell
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

3.  Protective immunity against mouse upper genital tract pathology correlates with high IFNγ but low IL-17 T cell and anti-secretion protein antibody responses induced by replicating chlamydial organisms in the airway.

Authors:  Chunxue Lu; Hao Zeng; Zhihong Li; Lei Lei; I-Tien Yeh; Yimou Wu; Guangming Zhong
Journal:  Vaccine       Date:  2011-11-10       Impact factor: 3.641

Review 4.  Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model.

Authors:  Christina M Farris; Richard P Morrison
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

5.  Chlamydia trachomatis persistence in the female mouse genital tract: inducible nitric oxide synthase and infection outcome.

Authors:  K H Ramsey; G S Miranpuri; I M Sigar; S Ouellette; G I Byrne
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

6.  Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization.

Authors:  Pooja Ralli-Jain; Delia Tifrea; Chunmei Cheng; Sukumar Pal; Luis M de la Maza
Journal:  Vaccine       Date:  2010-09-25       Impact factor: 3.641

Review 7.  Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system.

Authors:  H Y Wu; M W Russell
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

8.  Route of infection that induces a high intensity of gamma interferon-secreting T cells in the genital tract produces optimal protection against Chlamydia trachomatis infection in mice.

Authors:  J U Igietseme; I M Uriri; S N Kumar; G A Ananaba; O O Ojior; I A Momodu; D H Candal; C M Black
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

9.  Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239.

Authors:  Panagiotis Vagenas; Vennansha G Williams; Michael Piatak; Julian W Bess; Jeffrey D Lifson; James L Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12-01       Impact factor: 3.731

10.  A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge.

Authors:  Chunmei Cheng; Sukumar Pal; Delia Tifrea; Zhenyu Jia; Luis M de la Maza
Journal:  Microbes Infect       Date:  2013-11-27       Impact factor: 2.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.